In a study by Pandya S. et al. Six wistar female rats were given a single dose of coroprotect dry syrup at 2000 mg/kg by oral gavage, while doses of 100, 200 and 500 mg/kg/day were given over the course of 28 days in a repeated-dose subacute toxicity study. In an acute toxicity investigation involving coroprotect dry syrup administration, no therapies fatalities or toxic symptoms were found. In the repeated dosage study, there were no substantial differences in body weight fluctuations, food/water ingestion, haematology, or clinical biochemistry content among the control as well as coroprotect dry syrup groups. There were no gross pathological abnormalities or variations in relative organ weights between the control and coroprotect dry syrup groups. Histopathological investigation revealed no abnormalities after therapy with coroprotect dry syrup. Pandya S. et al. concluded that in a repeated dosage toxicity study in rodents, the coroprotect dry syrup was determined to be safe at all dose levels.
In a study by Keshav C. et al. antithrombotic activity [antiplatelet, activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT) assays] of standardized Dolichos biflorus seed extract (DBSE) and standardized Pterocarpus marsupium bark extract (PMBE) was determined. The study investigated the anticoagulant activities in vitro by performing activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT) assays. Antiplatelet aggregation activity of the extract was examined using adenosine diphosphate (ADP), collagen, and thrombin as agonists, and the inhibitions of factor Xa and thrombin were also investigated. Bleeding and clotting times in mice were used to determine its anticoagulant activities in vivo. This study is the first to show that DBSE and PMBE possess anticoagulant properties, most likely as a result of its capacity to block thrombin activity. DBSE and PMBE could be a thrombin inhibitor with anticoagulant therapeut
Comments
Post a Comment